Last Updated : October 25, 2005
Details
FilesGeneric Name:
Efalizumab
Project Status:
Complete
Therapeutic Area:
Psoriasis, moderate to severe chronic plaque
Manufacturer:
Serono Canada Inc.
Brand Name:
Raptiva
Project Line:
Reimbursement Review
Project Number:
SR0043-000
Performance Metric:
N/A — Predated performance metrics
Submission Type:
Initial
Indications:
Psoriasis, moderate to severe chronic plaque
Recommendation Type:
List with clinical criteria and/or conditions
Final Recommendation:
Recommendation:
(tentative)
Files
Last Updated : October 25, 2005